SEARCH

SEARCH BY CITATION

References

  • 1
    Nierenberg AA, Amsterdam JD. Resistant depression: Definition and treatment approaches. J. Clin. Psychiatry 1990; 51: S39S47.
  • 2
    Berlim MT, Turecki G. Definition, assessment, and staging of treatment-resistant refractory major depression: A review of current concepts and methods. Can. J. Psychiatry 2007; 52: 4654.
  • 3
    Trivedi MH, Rush AJ, Wisniewski SR. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. Am. J. Psychiatry 2006; 163: 2840.
  • 4
    DeBattista C, Hawkins J. Utility of atypical antipsychotics in the treatment of resistant unipolar depression. CNS Drugs 2009; 23: 369377.
  • 5
    Fava M. New approaches to the treatment of refractory depression. J. Clin. Psychiatry 2000; 61 (Suppl. 1): 2632.
  • 6
    Nelson JC. Augmentation strategies in depression. J. Clin. Psychiatry 2000; 61 (Suppl. 2): 1319.
  • 7
    Hirschfeld RM, Montgomery SA, Aguglia E et al. Partial response and nonresponse to antidepressant therapy: Current approaches and treatment options. J. Clin. Psychiatry 2002; 63: 826837.
  • 8
    Lam RW, Wan DDC, Cohen NL et al. Combining antidepressants for treatment-resistant depression: A review. J. Clin. Psychiatry 2002; 63: 685693.
  • 9
    Sackeim HA. The definition and meaning of treatment resistant depression. J. Clin. Psychiatry 2001; 62 (Suppl. 16): 1017.
  • 10
    De la Gándara J, Ágüera L, Ros S et al. Use of antidepressant combinations: Which, when and why? Results of a Spanish survey. Acta Psychiatr. Scand. 2005; 112: 3235.
  • 11
    Dodd S, Horgan D, Malhi GS et al. To combine or not to combine? A literature review of antidepressant combination therapy. J. Affect. Disord. 2005; 89: 111.
  • 12
    Rojo JE, Ros S, Agüera L et al. Combined antidepressant: Clinical experience. Acta Psychiatr. Scand. 2005; 112: 2531.
  • 13
    Brink CB, Harvey BH, Brand L. Tianeptine: A novel atypical antidepressant that may provide new insights into the biomolecular basis of depression. Recent Pat. CNS Drug Discov. 2006; 1: 2941.
  • 14
    Wagstaff AJ, Ormrod D, Spencer CM. Tianeptine: A review of its use in depressive disorders. CNS Drugs 2001; 15: 231259.
  • 15
    Guelfi JD, Bouhassira M, Bonett-Perrin E et al. The study of the efficacy of fluoxetine versus tianeptine in the treatment of elderly depressed patients followed in general practice. Encephale 1999; 25: 265270 [in French].
  • 16
    Lôo H, Saiz-Ruiz J, Costa-e-Silva JA et al. Efficacy and safety of tianeptine in the treatment of depressive disorders in comparison with fluoxetine. J. Affect. Disord. 1999; 56: 109118.
  • 17
    Waintraub L, Septien L, Azoulay P. Efficacy and safety of tianeptine in major depression: Evidence from a 3-month controlled clinical trial versus paroxetine [abstract]. Eur. Neuropsychopharmacol. 2000; 10 (Suppl. 2): S51.
  • 18
    McEwen BS, Chattarji S, Diamond DM et al. The neurobiological properties of tianeptine (Stablon): From monoamine hypothesis to glutamatergic modulation. Mol. Psychiatry 2010; 15: 237249.
  • 19
    Stablon. [package insert]. Servier, Neuilly-sur-Seine, France. Available from URL: http://www.servier.com/sites/default/files/SPC_Stablon.pdf (last accessed 9 April 2013).
  • 20
    Sokolov STH, Joffe RT. Practical guidelines for combination drug therapy of treatment-resistant depression. CNS Drugs 1995; 4: 341350.
  • 21
    Keller MB. Issues in treatment-resistant depression. J. Clin. Psychiatry 2005; 66 (Suppl. 8): 512.
  • 22
    Nelson JC, Mazure CM, Bowers MB Jr et al. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch. Gen. Psychiatry 1991; 48: 303307.
  • 23
    Nelson JC, Mazure CM, Jatlow PI et al. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: A double-blind, randomized study. Biol. Psychiatry 2004; 55: 296300.
  • 24
    Fava M, Rosenbaum JF, McGrath PJ et al. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: A double-blind, controlled study. Am. J. Psychiatry 1994; 151: 13721374.
  • 25
    Carpenter LL, Jocic Z, Hall JM et al. Mirtazapine augmentation in the treatment of refractory depression. J. Clin. Psychiatry 1999; 60: 4549.
  • 26
    Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol. Psychiatry 2002; 51: 183188.
  • 27
    Bodkin JA, Lasser RA, Wines JD et al. Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J. Clin. Psychiatry 1997; 58: 137145.
  • 28
    Kennedy SH, McCann SM, Masellis M et al. Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: A preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. J. Clin. Psychiatry 2002; 63: 181186.
  • 29
    Joffe RT. Substitution therapy in patients with major depression. CNS Drugs 1999; 11: 175180.
  • 30
    Trivedi MH, Fava M, Wisniewski SR et al. Medication augmentation after the failure of SSRIs for depression. N. Engl. J. Med. 2006; 354: 12431252.
  • 31
    Mennini T, Mocaer E, Garattini S. Tianeptine, a selective enhancer of serotonin uptake in rat brain. Naunyn Schmiedebergs Arch. Pharmacol. 1987; 336: 478482.
  • 32
    Fattaccini CM, Bolanos-Jimenez F, Gozlan H et al. Tianeptine stimulates uptake of 5-hydroxytryptamine in vivo in the rat brain. Neuropharmacology 1990; 29: 18.
  • 33
    Kuroda Y, Watanabe Y, McEwen BS. Tianeptine decreases both serotonin transporter mRNA and binding sites in rat brain. Eur. J. Pharmacol. 1994; 268: R3R5.
  • 34
    Malagie I, Deslandes A, Gardier AM. Effects of acute and chronic tianeptine administration on serotonin outflow in rats: Comparison with paroxetine by using in vivo microdialysis. Eur. J. Pharmacol. 2000; 403: 5565.
  • 35
    Pitra P, Tokarski K, Grzegorzewska M et al. Effects of repetitive administration of tianeptine, zinc hydroaspartate and electroconvulsive shock on the reactivity of 5-HT(7) receptors in rat hippocampus. Pharmacol. Rep. 2007; 59: 627635.
  • 36
    Uzbekov MG, Misionzhnik EY, Maximova NM et al. Biochemical profile in patients with anxious depression under the treatment with serotonergic antidepressants with different mechanisms of action. Hum. Psychopharmacol. 2006; 21: 109115.
  • 37
    Kasper S, McEwen BS. Neurobiological and clinical effects of the antidepressant tianeptine. CNS Drugs 2008; 22: 1526.
  • 38
    McEwen BS, Olie JP. Neurobiology of mood, anxiety, and emotions as revealed by studies of a unique antidepressant: Tianeptine. Mol. Psychiatry 2005; 10: 525537.
  • 39
    Kole MH, Swan L, Fuchs E. The antidepressant tianeptine persistently modulates glutamate receptor currents of the hippocampal CA3 commissural associational synapse in chronically stressed rats. Eur. J. Neurosci. 2002; 16: 807816.
  • 40
    McEwen BS, Chattarji S. Molecular mechanisms of neuroplasticity and pharmacological implications: The example of tianeptine. Eur. Neuropsychopharmacol. 2004; 14: S497S502.
  • 41
    Sen S, Sanacora G. Major depression: Emerging therapeutics. Mt Sinai J. Med. 2008; 75: 204225.
  • 42
    Swanson CJ, Bures M, Johnson MP et al. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat. Rev. Drug Discov. 2005; 4: 131144.
  • 43
    Hashimoto K. Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res. Rev. 2009; 61: 105123.
  • 44
    Musazzi L, Milanese M, Farisello P et al. Acute stress increases depolarization-evoked glutamate release in the rat prefrontal/frontal cortex: The dampening action of antidepressants. PLoS ONE 2010; 5: e8566.
  • 45
    Mocquard MT, Proust L, Deslandes A et al. Identification of the enzymes involved in the primary pathways of tianeptine using human in vitro models [abstract]. Eur. Neuropsychopharmacol. 1998; 8 (Suppl. 2): S206.
  • 46
    Vandel P, Regina W, Bonin B et al. Abuse of tianeptine: A case report. Encephale 1999; 25: 672673 [in French].
  • 47
    Guelfi JD, Dulcire C, Le Moine P et al. Clinical safety and efficacy of tianeptine in 1,858 depressed patients treated in general practice. Neuropsychobiology 1992; 25: 140148.
  • 48
    Cassano GB, Heinze G, Lôo H et al. A double-blind comparison of tianeptine, imipramine and placebo in the treatment of major depressive episodes. Eur. Psychiatry 1996; 11: 254259.
  • 49
    Costa e Silva JA, Ruschel SI, Caetano D et al. Placebo-controlled study of tianeptine in major depressive episodes. Neuropsychobiology 1997; 35: 2429.
  • 50
    Thase ME, Frank E, Mallinger AG et al. Treatment of imipramine-resistant recurrent depression, 3: Efficacy of monoamine oxidase inhibitors. J. Clin. Psychiatry 1992; 53: 511.
  • 51
    Nierenberg AA, Papakostas GI, Petersen T et al. Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants. J. Clin. Psychopharmacol. 2003; 64: 192196.
  • 52
    Stanley B. An integration of ethical and clinical considerations in the use of placebos. Psychopharmacol. Bull. 1988; 7: 7375.
  • 53
    Thase ME, Rush AJ. Strategies and tactics in the treatment of chronic depression. J. Clin. Psychiatry 1997; 58 (Suppl. 13): 1422.
  • 54
    Fromenty B, Freneaux E, Labbe G et al. Tianeptine, a new tricyclic antidepressant metabolized by β-oxidation of its heptanoic side chain, inhibits the mitochondrial oxidation of medium and short chain fatty acids in mice. Biochem. Pharmacol. 1989; 38: 37433751.
  • 55
    Balleyguier C, Stérin D, Ziol M et al. Acute mixed hepatitis caused by tianeptine (letter). Gastroenterol. Clin. Biol. 1996; 20: 607608 [in French].
  • 56
    Le Bricquir Y, Larrey D, Blanc P et al. Tianeptine: An instance of drug-induced hepatotoxicity predicted by prospective experimental studies. J. Hepatol. 1994; 21: 771773.
  • 57
    Rifflet H, Vuillemin E, Rifflet I et al. Acute painful and febrile hepatic involvement related to ingestion of tianeptine (letter). Gastroenterol. Clin. Biol. 1996; 20: 606607 [in French].
  • 58
    Wilde MI, Benfield P. Tianeptine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depression and coexisting anxiety and depression. Drugs 1995; 49: 411439.